Citations

Clear

9383 citation(s) found for "Thomas, PS".

Effect of lecithin on jejunal absorption of micellar lipids in man and on their monomer activity in vitro
Ammon, Helmut V., Thomas, Paul J., Phillipis, S. F.

Mayo Clinic

Lipids | November 22, 2006 | Volume: 14 | Issue: 4 | Pages: 395-400

10.1007/bf02533424 | PMID 440030 Get It

AbstractThe effect of lecithin on jejunal absorption of fatty acids and octadecenoylglycerol was studied in healthy volunteers with a jejunal perfusion system which excluded pancreatic and biliary secretions from the test segment. Lecithin significantly reduced the absorption of oleic acid (P<0.05) and octadecenoylglycerol (P<0.01), while it had no effect on the absorption of ricinoleic acid. In vitro, lecithin reduced monomer activities of all three lipids; the changes were greater for oleic acid and octadecenoylglycerol than for ricinoleic acid (P<0.02). From these data it is concluded that lecithin reduces monomer activity of fatty acids in mixed micellar solutions and that it can thereby reduce the absorption rates of micellar lipids. Intact lecithin is not absorbed under these conditions. Maldigestion of lecithin in pancreatic insufficiency may, therefore, aggravate the steatorrhea observed in this condition.
Methylenetetrahydrofolate Reductase Haplotype Tag Single-Nucleotide Polymorphisms and Risk of Breast Cancer
Martin, Yvette N. , Vierkant, Robert A. , Fredericksen, Zachary S., Wu, Yanhong , Schaid, Daniel J. , Sellers, Thomas A. , Weinshilboum, Richard M. , Olson, Janet E. , Ingle, James N. , Pankratz, V. Shane , Weinshilboum, Richard M. , Vierkant, Robert A

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 21, 2006 | Volume: 15 | Issue: 11 | Pages: 2322-2324

10.1158/1055-9965.epi-06-0318 | PMID 17119067 Get It

Gender-related differences in vascular smooth muscle cell proliferation: implications for prevention of arteriosclerosis
Fitzpatrick, Lorraine A. , Anderson, Joseph , Moraghan, Thomas J., Miller, Virginia M. , Ruan, Maggie

Mayo Clinic

Lupus | November 2, 2006 | Volume: 8 | Issue: 5 | Pages: 397-401

10.1177/096120339900800514 | PMID 10455521 Get It

Premenopausal women have a significant reduction in coronary artery disease compared to age matched males. Little is known about the mechanism underlying this cardio protective effect of estrogen. Contradictory evidence has been published and our lack of basic understanding of hormone interactions and bioavailability of different estrogens prevents definitive interpretation of these data. We demonstrate gender-specific effects in the proliferation of coronary artery vascular smooth muscle cells obtained from a sexually mature animal model. Vascular smooth muscle cells are an integral component of the atherosclerotic plaque, and inhibition of cell proliferation by estrogen may be one mechanism by which estrogen exerts its cardio protective effect. Various types of estrogen may also have different mechanistic actions on the vascular system. No differences are demonstrated in overall estradiol binding in vascular smooth muscle cells obtained from male or female animals; however, differences in c-jun, c-fos and TIEG gene expression were gender related. Inhibition of vascular smooth muscle cell proliferation may have important implications in the prevention of atherosclerotic disease and these studies may provide evidence for the cardio protective effect of estrogen.
Expression and Regulatory Role of GAIP-Interacting Protein GIPC in Pancreatic Adenocarcinoma
Muders, Michael H. , Dutta, Shamit K., Wang, Ling , Lau, Julie S., Smyrk, Thomas C. , Chari, Suresh T. , Datta, Kaustubh , Bhattacharya, Resham , Mukhopadhyay, Debabrata , Chari, Suresh T

Mayo Clinic

Cancer Research | November 2, 2006 | Volume: 66 | Issue: 21 | Pages: 10264-10268

10.1158/0008-5472.can-06-2321 | PMID 17079444 Get It

Abstract Regulator of G-protein signaling–GAIP-interacting protein COOH terminus (GIPC) is involved in protein trafficking, endocytosis, and receptor clustering and is associated with insulin-like growth factor I receptor (IGF-IR), a receptor important for proliferation and anchorage-independent growth. Here, we described GIPC expression in different human pancreatic adenocarcinoma (PCA) cell lines and we examined the role of GIPC in the regulation of IGF-IR protein levels in PCA. Interestingly, inhibition of GIPC expression by RNA interference led to reduced IGF-IR protein levels and a subsequent decrease in proliferation of PCA cells. We also determined that the PDZ domain of GIPC is essential for the post-translational regulation and the binding of IGF-IR. The importance of GIPC in pancreatic cancer development and progression is supported by tissue microarray data of 300 pancreatic cancer specimens where GIPC is highly expressed in PCA. Taken together, our data suggest that GIPC is a central molecule for the stability of IGF-IR and could be a target for future therapy. (Cancer Res 2006; 66(21): 10264-8)
Monitoring Thyroglobulin in a Sensitive Immunoassay Has Comparable Sensitivity to Recombinant Human TSH-Stimulated Thyroglobulin in Follow-Up of Thyroid Cancer Patients
Smallridge, Robert C., Meek, Shon , Morgan, Melissa A., Gates, Geoffrey S., Fox, Thomas Peter , Grebe, Stefan K., Fatourechi, Vahab

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | November 1, 2006 | Volume: 92 | Issue: 1 | Pages: 82-87

10.1210/jc.2006-0993 | PMID 17077133 Get It

Abstract Context: Most thyroglobulin (Tg) assays have a sensitivity of 0.5–1 ng/ml. A minority of patients with undetectable T4-suppressed Tg levels have a recombinant human TSH (rhTSH)-stimulated Tg above 2 ng/ml and identifiable residual disease. Objective: The objective was to determine whether a Tg assay with improved sensitivity could eliminate the need for rhTSH stimulation when baseline Tg is below 0.1 ng/ml. Design: A retrospective study of two academic endocrine practices was conducted. Population: A total of 194 patients undergoing rhTSH stimulation participated in the study. Results: Of the 80 patients with Tg below 0.1 ng/ml, two (2.5%) had rhTSH-stimulated Tg above 2 ng/ml. One other patient with stimulation to 0.3 ng/ml and negative 123I scan had an ultrasound-detected malignant lymph node resected. None had 131I/123I imaging after rhTSH stimulation suggestive of local recurrence or distant metastasis. If T4-suppressed Tg was 0.1–0.5 or 0.6–2.0 ng/ml, rhTSH Tg was above 2 ng/ml in 24.2 and 82.4%, respectively. Conclusions: Patients with differentiated thyroid carcinoma and a T4-suppressed serum Tg below 0.1 ng/ml rarely have a rhTSH-stimulated Tg above 2 ng/ml, and none of these patients had 131I or 123I imaging after rhTSH stimulation suggestive of local recurrence or distant metastasis. We recommend monitoring such patients with a T4-suppressed Tg level and periodic neck ultrasonography. An increase in T4-suppressed serum Tg to a detectable level or the appearance of abnormal lymph nodes by physical or ultrasound exam should prompt further investigation.
Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain
Liang, Winnie S. , Dunckley, Travis , Beach, Thomas G. , Grover, Andrew, Mastroeni, Diego , Walker, Douglas G. , Caselli, Richard J. , Kukull, Walter A. , McKeel, Daniel W., Morris, John C. , Hulette, Christine, Schmechel, Donald E., Alexander, Gene E. , Reiman, Eric M. , Rogers, Joseph, Stephan, Dietrich A. , Morris, John C

Mayo Clinic

Physiological Genomics | October 31, 2006 | Volume: 28 | Issue: 3 | Pages: 311-322

10.1152/physiolgenomics.00208.2006 | PMID 17077275 Get It

In this article, we have characterized and compared gene expression profiles from laser capture microdissected neurons in six functionally and anatomically distinct regions from clinically and histopathologically normal aged human brains. These regions, which are also known to be differentially vulnerable to the histopathological and metabolic features of Alzheimer’s disease (AD), include the entorhinal cortex and hippocampus (limbic and paralimbic areas vulnerable to early neurofibrillary tangle pathology in AD), posterior cingulate cortex (a paralimbic area vulnerable to early metabolic abnormalities in AD), temporal and prefrontal cortex (unimodal and heteromodal sensory association areas vulnerable to early neuritic plaque pathology in AD), and primary visual cortex (a primary sensory area relatively spared in early AD). These neuronal profiles will provide valuable reference information for future studies of the brain, in normal aging, AD and other neurological and psychiatric disorders.
A Systematic Method for Selection of Promising Serum Protein Biomarkers to Improve Prostate Cancer (PCa1) Detection
Finlay, Judith A., Klee, Eric W. , McDonald, Cari, Attewell, John R., Hebrink, Deanne, Dyer, Roy B. , Vasmatzis, George , Li, Thomas M, Beechem, Joseph , Klee, George G., Love, Brad

Mayo Clinic

Clinical Chemistry | October 26, 2006 | Volume: 52 | Issue: 11 | Pages: 2159-2162

10.1373/clinchem.2006.072959 | PMID 18061988 Get It

Bioinformatics Methods for Prioritizing Serum Biomarker Candidates
Klee, Eric W. , Finlay, Judith A., McDonald, Cari, Attewell, John R., Hebrink, Deanne, Dyer, Roy B. , Vasmatzis, George , Li, Thomas M, Beechem, Joseph , Klee, George G., Love, Brad

Mayo Clinic

Clinical Chemistry | October 26, 2006 | Volume: 52 | Issue: 11 | Pages: 2162-2164

10.1373/clinchem.2006.072868 | PMID 18061989 Get It

Randomized Phase II Study of Interleukin-12 in Combination with Rituximab in Previously Treated Non-Hodgkin's Lymphoma Patients
Ansell, Stephen M. , Geyer, Susan M. , Maurer, Matthew J. , Kurtin, Paul J. , Micallef, Ivana N. , Stella, Philip J., Etzell, Paul S., Novak, Anne J. , Erlichman, Charles , Witzig, Thomas E. , Maurer, Matthew

Mayo Clinic

Clinical Cancer Research | October 24, 2006 | Volume: 12 | Issue: 20 | Pages: 6056-6063

10.1158/1078-0432.ccr-06-1245 | PMID 17062681 Get It

Abstract Purpose: Rituximab is a chimeric antibody that induces B-cell apoptosis and recruits immune effector cells to mediate cell lysis. Interleukin-12 (IL-12) facilitates cytolytic responses by T cells and natural killer cells. This phase II study was done to determine the efficacy and toxicity of IL-12 in combination with rituximab in patients with B-cell non-Hodgkin's lymphoma (NHL). Experimental Design: Fifty-eight patients with histologically confirmed relapsed B-cell NHL were randomized to receive concurrent treatment with rituximab and IL-12 (arm A) or rituximab with subsequent treatment with IL-12 after documented nonresponse or progression after rituximab (arm B). Treatment consisted of 375 mg/m2 rituximab on days 1, 8, 15, and 22 and 300 ng/kg IL-12 given s.c. twice weekly starting on day 2 for arm A or upon progression for arm B. Results: The overall response rate was 37% (11 of 30) in arm A and 52% (13 of 25) in arm B. All of the responses seen in arm B occurred while patients received rituximab, and no responses occurred during treatment with subsequent IL-12. The median duration of response was 16 months for arm A and 12 months for arm B. Biopsy specimens were serially obtained in a subset of patients and showed that changes in gene expression were different when cells from the peripheral blood were compared with cells from lymph node biopsies. Conclusions: The concomitant use of IL-12 and rituximab had modest disease activity in patients with B-cell NHL, but the sequential administration of IL-12 after rituximab did not result in additional clinical responses.
Family history of stroke and severity of neurologic deficit after stroke
Case, L. Douglas, Worrall, Bradford B. , Brown, Robert D., Brott, Thomas G. , Frankel, Michael , Silliman, Scott, Rich, Stephen S. , Meschia, James F. , Rich, Stephen S

Mayo Clinic

Neurology | October 24, 2006 | Volume: 67 | Issue: 8 | Pages: 1396-1402

10.1212/01.wnl.0000240267.25699.9d | PMID 17060565 Get It